[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. [2] 叶定伟, 朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4):249-252. [3] Tawfik A. Prostate-specific antigen (PSA)-based population screening for prostate cancer: an economic analysis[J]. Ont Health Technol Assess Ser, 2015, 15(11):1-37. [4] Force U,Grossman DC,Curry SJ,et al. Screening for prostate cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 319(18):1901-1913. [5] Greenberg P,Cox C,LeBeau MM,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood, 1997, 89(6):2079-2088. [6] 戴波.前列腺癌筛查专家共识[J].中华外科杂志,2017,55(5):340-342. [7] Ritch CR, Morrison BF, Hruby G, et al. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison[J]. BJU Int, 2013, 111(4PtB):E186-190. [8] Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the EuropeanRandomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up[J]. Lancet, 2014, 384(9959):2027-2035. [9] Vickers AJ, Sjoberg DD, Ulmert D, et al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen[J]. BMC Med, 2014, 12(1):26. [10] 张舒娴, 王泽洲, 施榕, 等. 社区非前列腺癌男性人群血清前列腺特异性抗原影响因素研究[J]. 中华全科医学, 2019, 17(2):252-255. [11] 梁桂锋,罗杰鑫,卢建军,等.298例中老年良性前列腺增生患者生活质量及影响因素调查分析[J].实用预防医学,2020,27(6):721-723. [12] 徐晓峰, 贺大林, 王明珠,等. 手术治疗的良性前列腺增生患者年龄与血清PSA、PSAD的关系分析[J]. 现代泌尿外科杂志, 2009, 14(6):455-457. [13] 顾成元, 秦晓健, 黄永墙,等. 我国部分省市前列腺癌精准筛查初步结果分析[J]. 中华医学杂志, 2019, 99(42):3292-3297.
2022, Vol. 29 
